53. シェーグレン症候群 Sjogren syndrome Clinical trials / Disease details


臨床試験数 : 305 薬物数 : 325 - (DrugBank : 104) / 標的遺伝子数 : 58 - 標的パスウェイ数 : 188

  
7 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2014-004523-51-GR
(EUCTR)
14/02/201703/01/2017UCB Proof of Concept Study in patients with Primary Sjogren’s SyndromeA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF-OF-CONCEPT STUDY TO EVALUATE THE EFFICACY AND SAFETY OF UCB5857 OVER 12 WEEKS IN SUBJECTS WITH PRIMARY SJOGREN’S SYNDROME Primary Sjogren’s Syndrome
MedDRA version: 19.0;Level: PT;Classification code 10040767;Term: Sjogren's syndrome;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: UCB5857
Product Code: UCB5857
INN or Proposed INN: UCB5857
Other descriptive name: UCB5857
Product Name: UCB5857
Product Code: UCB5857
INN or Proposed INN: UCB5857
Other descriptive name: UCB5857
Product Name: UCB5857
Product Code: UCB5857
INN or Proposed INN: UCB5857
Other descriptive name: UCB5857
UCB Celltech, UKNULLNot RecruitingFemale: yes
Male: yes
58Phase 2France;Greece;Spain;Italy;United Kingdom;Sweden
2EUCTR2014-004523-51-SE
(EUCTR)
24/08/201605/07/2016UCB Proof of Concept Study in patients with Primary Sjogren’s SyndromeA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF-OF-CONCEPT STUDY TO EVALUATE THE EFFICACY AND SAFETY OF UCB5857 OVER 12 WEEKS IN SUBJECTS WITH PRIMARY SJOGREN’S SYNDROME Primary Sjogren’s Syndrome
MedDRA version: 19.0;Level: PT;Classification code 10040767;Term: Sjogren's syndrome;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: UCB5857
Product Code: UCB5857
INN or Proposed INN: UCB5857
Other descriptive name: UCB5857
Product Name: UCB5857
Product Code: UCB5857
INN or Proposed INN: UCB5857
Other descriptive name: UCB5857
Product Name: UCB5857
Product Code: UCB5857
INN or Proposed INN: UCB5857
Other descriptive name: UCB5857
UCB Celltech, UKNULLNot RecruitingFemale: yes
Male: yes
58Phase 2France;Greece;Spain;Netherlands;Italy;United Kingdom;Sweden
3NCT02610543
(ClinicalTrials.gov)
October 201518/11/2015UCB Proof of Concept Study in Patients With Primary Sjögren's SyndromeA Randomized, Double-blind, Placebo-controlled, Proof-of-concept Study to Evaluate the Efficacy of UCB5857 Over 12 Weeks in Subjects With Primary Sjögren's SyndromePrimary Sjögren's SyndromeDrug: UCB5857;Drug: PlaceboUCB CelltechPRA Health SciencesTerminated18 Years75 YearsAll27Phase 2France;Italy;Spain;Sweden;United Kingdom;Greece
4EUCTR2014-004523-51-ES
(EUCTR)
14/09/201501/06/2015UCB Proof of Concept Study in patients with Primary Sjogren?s SyndromeA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF-OF-CONCEPT STUDY TO EVALUATE THE EFFICACY AND SAFETY OF UCB5857 OVER 12 WEEKS IN SUBJECTS WITH PRIMARY SJOGREN?S SYNDROME Primary Sjogren?s Syndrome
MedDRA version: 18.0;Level: PT;Classification code 10040767;Term: Sjogren's syndrome;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: UCB5857
Product Code: UCB5857
INN or Proposed INN: UCB5857
Other descriptive name: UCB5857
Product Name: UCB5857
Product Code: UCB5857
INN or Proposed INN: UCB5857
Other descriptive name: UCB5857
Product Name: UCB5857
Product Code: UCB5857
INN or Proposed INN: UCB5857
Other descriptive name: UCB5857
UCB Celltech, UKNULLNot RecruitingFemale: yes
Male: yes
58Phase 2France;Greece;Spain;Netherlands;Italy;United Kingdom;Sweden
5EUCTR2014-004523-51-IT
(EUCTR)
25/08/201515/12/2017UCB PROOF OF CONCEPT STUDY IN PATIENTS WITH PRIMARY SJ?GREN'S SYNDROMEA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF-OFCONCEPTSTUDY TO EVALUATE THE EFFICACY AND SAFETY OF UCB5857 OVER 12 WEEKS IN SUBJECTS WITH PRIMARY SJ?GREN'S SYNDROME - NA Primary Sj?gren's Syndrome
MedDRA version: 20.0;Level: PT;Classification code 10040767;Term: Sjogren's syndrome;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: UCB5857
Product Code: UCB5857
INN or Proposed INN: UCB5857
Other descriptive name: UCB5857
Product Name: UCB5857
Product Code: UCB5857
INN or Proposed INN: UCB5857
Other descriptive name: UCB5857
Product Name: UCB5857
Product Code: UCB5857
INN or Proposed INN: UCB5857
Other descriptive name: UCB5857
UCB CELLTECH (UK BRANCH OF UCB PHARMA SA)NULLNot RecruitingFemale: yes
Male: yes
58Phase 2France;Greece;Spain;Netherlands;United Kingdom;Italy;Sweden
6EUCTR2014-004523-51-FR
(EUCTR)
28/05/201520/07/2015UCB Proof of Concept Study in patients with Primary Sjogren’s SyndromeA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF-OF-CONCEPT STUDY TO EVALUATE THE EFFICACY AND SAFETY OF UCB5857 OVER 12 WEEKS IN SUBJECTS WITH PRIMARY SJOGREN’S SYNDROME Primary Sjogren’s Syndrome
MedDRA version: 18.0;Level: PT;Classification code 10040767;Term: Sjogren's syndrome;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: UCB5857
Product Code: UCB5857
INN or Proposed INN: UCB5857
Other descriptive name: UCB5857
Product Name: UCB5857
Product Code: UCB5857
INN or Proposed INN: UCB5857
Other descriptive name: UCB5857
Product Name: UCB5857
Product Code: UCB5857
INN or Proposed INN: UCB5857
Other descriptive name: UCB5857
UCB Celltech, UKNULLNot RecruitingFemale: yes
Male: yes
58Phase 2France;Greece;Spain;Netherlands;Italy;United Kingdom;Sweden
7EUCTR2014-004523-51-GB
(EUCTR)
18/05/201501/04/2015UCB Proof of Concept Study in patients with Primary Sjogren’s SyndromeA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF-OF-CONCEPT STUDY TO EVALUATE THE EFFICACY AND SAFETY OF UCB5857 OVER 12 WEEKS IN SUBJECTS WITH PRIMARY SJOGREN’S SYNDROME Primary Sjogren’s Syndrome
MedDRA version: 19.1;Level: PT;Classification code 10040767;Term: Sjogren's syndrome;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: UCB5857
Product Code: UCB5857
INN or Proposed INN: UCB5857
Other descriptive name: UCB5857
Product Name: UCB5857
Product Code: UCB5857
INN or Proposed INN: UCB5857
Other descriptive name: UCB5857
Product Name: UCB5857
Product Code: UCB5857
INN or Proposed INN: UCB5857
Other descriptive name: UCB5857
UCB Celltech, UKNULLNot RecruitingFemale: yes
Male: yes
58Phase 2France;Greece;Spain;Italy;United Kingdom;Sweden